RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.

Private Company Edition: Kriya raised the first $270m of its now $430m-plus series C venture capital round in May 2022 and has raised more than $600m to date. Also, Nexo launched with $60m in series A cash, Ossium brought in $52m in series A financing and cell therapy CDMO Kincell launched with $36m.

Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.

Milan's Dompé Biotec is arguably Italy's leading marketer of biotechnology products. The wholly-owned subsidiary of Dompé Farmaceutici SPA gained access to three early products of biotechnology by allying with the large multinational firms that held European rights to them. But the privately held Italian firm has since made a point of directly pursuing American biotech companies, because they have what it wants: innovative treatments for specific medical conditions. But even the most carefully considered in-licensing deals won't help Dompé grow as fast as its owners would like. The firm, now intent on expanding its reach beyond Italy, hopes its past marketing experience will attract new partners.